These LATS1/2-null tumor cells induced type I interferon production by releasing EVs and activating the TLRs-MYD88/TRIF pathway, thereby potentiating tumor immunogenicity and effectively suppressing melanoma growth. Here, LATS1 is linked to neoplasm.